



Financial Tear Sheet

Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Primary IR Contact

Michael Booth, D.Phil.
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: mbooth@incyte.com

Stock Performance

INCY (Common)

Exchange	NASDAQ (US Dollar)
Price	\$134.22
Change (%)	▲ 0.43 (0.32%)
Volume	755,991
52 Week Low	\$75.52
Market Cap	\$27,484,821,176
Rolling EPS	-0.54
PE Ratio	N/A

Shares Outstanding 204,774,409

Data as of July 21, 2017 4:00 p.m. ET



Recent Headlines

July 20, 2017

[Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease](#)

July 11, 2017

[Incyte to Report Second Quarter Financial Results](#)

July 03, 2017

[Japan Ministry of Health, Labor and Welfare \(MHLW\) Grants Marketing Approval For Olumiant® \(baricitinib\) for the Treatment of Rheumatoid Arthritis](#)

Events

Date	Title
08/01/17 10:00 a.m. ET	Q2 2017 Incyte Corporation Earnings Conference Call

Data provided by Nasdaq. Minimum 15 minutes delayed.